Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

E. Ciruelos*, G. Jerusalem, M. Martin, V. C. G. Tjan-Heijnen, P. Neven, J. Gavila, F. Montemurro, D. Generali, I. Lang, M. J. Martinez-Serrano, M. F. Perello, P. Conte

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1857-1866
Number of pages10
JournalClinical & Translational Oncology
Volume22
Issue number10
DOIs
Publication statusPublished - Oct 2020

Keywords

  • Aromatase inhibitors
  • Breast neoplasm
  • Endocrine therapy
  • Everolimus
  • Post-menopausal women
  • Targeted therapy
  • PLACEBO-CONTROLLED TRIAL
  • ENDOCRINE THERAPY
  • POSTMENOPAUSAL WOMEN
  • DOUBLE-BLIND
  • SINGLE-ARM
  • FULVESTRANT
  • RESISTANCE
  • SAFETY
  • MULTICENTER
  • PALBOCICLIB

Cite this